5,000 patients treated with OssDsign Catalyst® in the U.S.
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst.
The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.
“With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it's accelerating. This is a significant leap from the earlier announcements of 2,000 patients treated in September 2023 and 1,000 patients in May 2023, demonstrating the rapid pace with which we are building our orthobiologics business,” said Morten Henneveld, CEO of OssDsign.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. 12-month results from the clinical study TOP FUSION, published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.
